Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis, a clinical-stage biopharmaceutical company, focuses on pioneering allogeneic CAR-T immunotherapies. As of May 31, 2021, the company reported a total of 45,461,310 shares in circulation and 51,531,739 voting rights. Cellectis aims to develop life-saving UCART product candidates for cancers like AML, B-ALL, and MM, leveraging its TALEN^® gene editing technology. The company's headquarters are in Paris, with operational sites in New York and Raleigh. Cellectis is listed on the Nasdaq (ticker: CLLS) and Euronext Growth (ticker: ALCLS).

Positive

• Developing innovative allogeneic CAR-T therapies with potential market impact.
• Evidence of strong corporate governance with a healthy share and voting rights structure.
• Dedicated to addressing unmet medical needs in multiple cancer types.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
05/31/2021	45,461,310	51,531,739

About Cellectis
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN^®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN^® is a registered trademark owned by Cellectis.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com

IR contact:
Simon Harnest, Chief Investment Officer, 646-385-9008, simon.harnest@cellectis.com 

Attachment

• Voting_Rights_PR_May_EN.pdf

FAQ

What recent updates have been reported by Cellectis (CLLS)?

Cellectis reported its share and voting rights structure as of May 31, 2021, with 45,461,310 shares and 51,531,739 voting rights.

Where is Cellectis headquartered?

Cellectis is headquartered in Paris, France, with additional sites in New York and Raleigh.

What products is Cellectis developing for cancer treatment?

Cellectis is developing UCART product candidates targeting cancers such as acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma.

Which gene editing technology does Cellectis use?

Cellectis utilizes the TALEN® gene editing technology for its CAR-T immunotherapies.

On which stock exchanges is Cellectis listed?

Cellectis is listed on the Nasdaq Global Market with the ticker symbol CLLS and on Euronext Growth with the ticker ALCLS.